Torrent Pharmaceuticals Limited , one of India's leading pharmaceutical companies, has announced robust financial results for the first quarter, along with a significant leadership change.

Strong Financial Performance

The company reported a 20% year-on-year increase in net profit, reaching Rs 548.00 crore for the quarter. This growth was driven by an 11% rise in revenue, which stood at Rs 3,178.00 crore.

Key financial highlights for Q1 include:

The company maintained a strong operating EBITDA margin of 32.5% and a gross margin of 76%.

Market Performance

Torrent Pharma outperformed in several key markets:

• India: Revenues grew by 11% to Rs 1,811.00 crore, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%. The company's chronic business grew by 13%, compared to the IPM's 9% growth in this segment.

• Brazil: Revenues increased by 11% to Rs 218.00 crore, with constant currency growth of 16%. Torrent's growth of 14% outpaced the market growth of 5%.

• Germany: Revenues rose by 9% to Rs 308.00 crore, with constant currency growth of 1%.

• United States: The US business saw a significant 19% increase in revenues to Rs 308.00 crore, with constant currency growth of 16%.

Leadership Transition

In a separate announcement, Torrent Pharmaceuticals' shareholders approved the appointment of Aman Mehta as Managing Director and Whole-time Key Managerial Personnel for a 5-year term beginning August 1, 2025.

Aman Mehta, who holds an economics degree from Boston University and an MBA from Columbia University, has been with Torrent for over 10 years. During his tenure as Whole-time Director, he has led several key initiatives:

• Expanding the field force from 3,600 to 6,400 medical representatives
• Improving the cardiac portfolio performance
• Elevating the diabetes portfolio ranking from 11th to 6th position
• Launching the Consumer Health Division
• Overseeing R&D and operations functions

Mehta has also played crucial roles in integrating acquisitions, including Unichem and Curatio Healthcare.

Strategic Acquisition

Torrent Pharmaceuticals has entered into a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The transaction, subject to regulatory approvals, will be executed in two phases:

1. Acquisition of up to 46.39% equity stake at Rs 1,600.00 per share, followed by a mandatory open offer for up to 26% additional stake.
2. Merger of JB Pharma with Torrent Pharmaceuticals through a scheme of arrangement.

This strategic move is expected to further strengthen Torrent's position in the pharmaceutical market.

As Torrent Pharmaceuticals continues to grow and evolve, the combination of strong financial performance, strategic leadership changes, and expansion initiatives positions the company for continued success in the competitive pharmaceutical landscape.

Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, showcasing significant growth across key metrics and markets.

Financial Highlights

• Revenue reached Rs. 3,178.00 crores, marking an 11% year-over-year increase
• Operating EBITDA grew by 14% to Rs. 1,032.00 crores
• Net profit after tax surged by 20% to Rs. 548.00 crores
• R&D spend increased by 16% to Rs. 157.00 crores, representing 5% of revenue

Strong Performance Across Markets

India

• India revenues rose by 11% to Rs. 1,811.00 crores, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%
• Chronic business grew by 13%, compared to IPM growth of 9% in this segment
• 21 brands featured in the Top 500 IPM brands, with 14 brands exceeding Rs. 100.00 crores in sales

Brazil

• Brazil revenues increased by 11% to Rs. 218.00 crores
• Constant currency revenues grew by 16% to R$ 143.00 million
• Torrent's growth of 14% outpaced the market growth of 5%
• 62 products are currently under review by ANVISA, Brazil's health regulatory agency

Germany

• Germany revenues grew by 9% to Rs. 308.00 crores
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party supplier

United States

• US business revenues surged by 19% to Rs. 308.00 crores
• Constant currency revenues increased by 16% to $36.00 million
• Recent product launches have achieved targeted market shares

Financial Position and Profitability

The company maintained strong profitability metrics:

Net profit margin improved from 16.00% in the same quarter last year.

Strategic Developments

Torrent Pharmaceuticals has entered into a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The proposed transaction, subject to regulatory approvals, will be executed in two phases:

1. Acquisition of up to 74.80% equity stake in JB Pharma through a combination of direct purchase and an open offer
2. Subsequent merger of JB Pharma with Torrent Pharmaceuticals

This strategic move is expected to strengthen Torrent's position in the Indian pharmaceutical market.

Research and Development

Torrent Pharma continues to invest heavily in R&D, with spending reaching Rs. 157.00 crores in Q1, representing 5% of revenue. The company's focus on innovation is evident in its product pipeline and market performance.

Conclusion

Torrent Pharmaceuticals' Q1 results demonstrate the company's strong growth trajectory and operational efficiency. With robust performance across key markets, strategic expansion plans, and continued focus on R&D, Torrent Pharma is well-positioned for sustained growth in the competitive pharmaceutical landscape.

Note: All financial figures are in Indian Rupees (INR) unless otherwise stated.